Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2021 3
2022 9
2023 13
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
From A to m6A: The Emerging Viral Epitranscriptome.
Baquero-Perez B, Geers D, Díez J. Baquero-Perez B, et al. Among authors: geers d. Viruses. 2021 Jun 1;13(6):1049. doi: 10.3390/v13061049. Viruses. 2021. PMID: 34205979 Free PMC article. Review.
Immunogenicity of the mRNA-1273 COVID-19 vaccine in adult patients with inborn errors of immunity.
van Leeuwen LPM, GeurtsvanKessel CH, Ellerbroek PM, de Bree GJ, Potjewijd J, Rutgers A, Jolink H, van de Veerdonk F, van Gorp ECM, de Wilt F, Bogers S, Gommers L, Geers D, Bruns AHW, Leavis HL, van Haga JW, Lemkes BA, van der Veen A, de Kruijf-Bazen SFJ, van Paassen P, de Leeuw K, van de Ven AAJM, Verbeek-Menken PH, van Wengen A, Arend SM, Ruten-Budde AJ, van der Ent MW, van Hagen PM, Sanders RW, Grobben M, van der Straten K, Burger JA, Poniman M, Nierkens S, van Gils MJ, de Vries RD, Dalm VASH. van Leeuwen LPM, et al. Among authors: geers d. J Allergy Clin Immunol. 2022 Jun;149(6):1949-1957. doi: 10.1016/j.jaci.2022.04.002. Epub 2022 Apr 11. J Allergy Clin Immunol. 2022. PMID: 35421449 Free PMC article. Clinical Trial.
Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern.
Schmitz KS, Geers D, de Vries RD, Bovier TF, Mykytyn AZ, Geurts van Kessel CH, Haagmans BL, Porotto M, de Swart RL, Moscona A. Schmitz KS, et al. Among authors: geers d. mBio. 2022 Jun 28;13(3):e0124922. doi: 10.1128/mbio.01249-22. Epub 2022 Jun 13. mBio. 2022. PMID: 35695453 Free PMC article.
Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Geers D, Schmitz KS, Garcia Garrido HM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Lafeber M, van Baarle D, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH Research Group. Sablerolles RSG, et al. Among authors: geers d. N Engl J Med. 2022 Mar 10;386(10):951-963. doi: 10.1056/NEJMoa2116747. Epub 2022 Jan 19. N Engl J Med. 2022. PMID: 35045226 Free PMC article. Clinical Trial.
The role of interleukin-21 in COVID-19 vaccine-induced B cell-mediated immune responses in patients with kidney disease and kidney transplant recipients.
Malahe SRK, Hartog YD, Rietdijk WJR, van Baarle D, de Kuiper R, Reijerkerk D, Ras AM, Geers D, Diavatopoulos DA, Messchendorp AL, van der Molen RG, Remmerswaal EBM, Bemelman FJ, Gansevoort RT, Hilbrands LB, Sanders JS, GeurtsvanKessel CH, Kho MML, de Vries RD, Reinders MEJ, Baan CC; RECOVAC Consortium RECOVAC collaborators. Malahe SRK, et al. Among authors: geers d. Am J Transplant. 2023 Sep;23(9):1411-1424. doi: 10.1016/j.ajt.2023.05.025. Epub 2023 Jun 1. Am J Transplant. 2023. PMID: 37270109 Free PMC article.
Durability of Immune Responses After Boosting in Ad26.COV2.S-Primed Healthcare Workers.
Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Schmitz KS, Geers D, Bogers S, van Haren E, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, Akkerman R, Beukema M, Lafeber M, van Baarle D, de Vries RD, van der Kuy PHM, GeurtsvanKessel CH; SWITCH Research Group. Sablerolles RSG, et al. Among authors: geers d. Clin Infect Dis. 2023 Feb 8;76(3):e533-e536. doi: 10.1093/cid/ciac495. Clin Infect Dis. 2023. PMID: 35723273 Free PMC article.
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan NH, Geers D, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, van Dijk LLA, Gommers L, van Leeuwen LPM, Boerma A, Nijhof SH, van Dort KA, Koopmans MPG, Dalm VASH, Lafeber M, Kootstra NA, Huckriede ALW, van Baarle D, Zaeck LM, GeurtsvanKessel CH, de Vries RD, van der Kuy PHM; SWITCH ON Research Group. Tan NH, et al. Among authors: geers d. Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
Infection of ferrets with wild type-based recombinant canine distemper virus overwhelms the immune system and causes fatal systemic disease.
Laksono BM, Roelofs D, Comvalius AD, Schmitz KS, Rijsbergen LC, Geers D, Nambulli S, van Run P, Duprex WP, van den Brand JMA, de Vries RD, de Swart RL. Laksono BM, et al. Among authors: geers d. mSphere. 2023 Aug 24;8(4):e0008223. doi: 10.1128/msphere.00082-23. Epub 2023 Jun 28. mSphere. 2023. PMID: 37377421 Free PMC article.
Analyzing the immunogenicity of bivalent booster vaccinations in healthcare workers: The SWITCH ON trial protocol.
Tan NH, Sablerolles RSG, Rietdijk WJR, Goorhuis A, Postma DF, Visser LG, Bogers S, Geers D, Zaeck LM, Koopmans MPG, Dalm VASH, Kootstra NA, Huckriede ALW, van Baarle D, Lafeber M, GeurtsvanKessel CH, de Vries RD, van der Kuy PM. Tan NH, et al. Among authors: geers d. Front Immunol. 2022 Nov 29;13:1067749. doi: 10.3389/fimmu.2022.1067749. eCollection 2022. Front Immunol. 2022. PMID: 36524126 Free PMC article.
27 results